InspireMD Inc (NYSEAMERICAN: NSPR) is having an overwhelmingly strong start to the trading session this morning after announcing the presentation of expanded data from a key clinical study. Of course, the news excited investors, leading to strong gains in the value of the stock. Today, we’ll talk about:
- The news;
- what we’re seeing from the stock;
- and what we’ll be watching for with regard to NSPR ahead.
NSPR Announces The Presentation Of Clinical Data
As mentioned above, InspireMD is having an incredibly strong start to the trading session this morning after announcing the presentation of data. In a press release issued early this morning, the copany announced that Professor Piotr Musialek presented the expanded 24 month follow-up results from the PARADIGM-Extended Clinical Study. During the study, CGuard™ EPS was the center of attention as a treatment for patients with symptomatic or asymptomatic carotid artery stenosis with increased stroke risk.
In the release, NSPR said that the results included 251 patients with data showing no major strokes in the peri-procedural or post-procedural period of up to 30 days. However, there was one minor per-procedural stroke, and only one death which was non-device related, at 30 days. Finally, there were no strokes, nor stroke-related deaths between months 12 and 24. In a statement, Professor Musialek had the following to offer:
The 24-month clinical and duplex ultrasound evidence is consistent with the unprecedented, sustained safety and cerebral embolism prevention efficacy of CGuard™ EPS in both symptomatic and asymptomatic patients with carotid stenosis.
The above statement was followed up by James Barry, PhD, CEO at NSPR. Here’s what he had to offer:
We feel privileged to have had Professor Musialek, one of the leading interventional cardiologists in Europe, present his expanded results of the PARADIGM study at EuroPCR 2018… Professor Musialek’s PARADIGM-Extend trial continues to demonstrate consistent and strong clinical evidence of durable protection against potential stroke that can result from post procedural embolization. In addition, the duplex ultrasound data confirms normal vessel healing with the CGuard™ EPS device and with no indication of any long term in-stent restenosis. These results include a significant proportion of challenging patients that would have otherwise been sent to surgery (carotid endarterectomy). Furthermore, these results are consistent with other CGuard™ EPS clinical trials including: CARENET, IRON-GUARD, WISSGOTT Study and CASANA Study. This excellent data continues to build on the extensive body of evidence supporting the clinical advantages of CGuard™ EPS in preventing stroke that can result from high grade carotid stenosis.
What We’re Seeing From The Stock
As we know, the news moves the market. In this particular case, the news proved to be overwhelmingly positive. After all, what’s better in the biotechnology space than positive clinical data. Considering this, it’s no surprise to see that excited investors are sending the stock on a run for the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:07), NSPR is trading at $1.31 per share after a gain of $0.11 per share or 9.17% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on NSPR. In particular, we’re interested in following the continued news surrounding the CGuard™ EPS device as the treatment is proving to be promising. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!